RxDoctor Payments Data

Stuart Andersen, MD

Internal Medicine · San Diego, CANPI 1205270956

Payments from drug & device makers

$1,214in general payments, 2019–2025

Across 53 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$313
  • Gilead$259
  • Viiv Healthcare Company$207
  • GSK$109
  • Lilly USA, LLC$57
  • EMD Serono, Inc.$47
  • plus $222 from 9 others

What the payments were for

  • Food & beverage$1,214100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,214 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$82,134
Medicare patients
421
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$15,934
Ventolin HfaAlbuterol Sulfate24$1,344
Ipratropium Bromide31$812
Gabapentin46$684
Potassium Chloride45$487
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen34$362
Albuterol Sulfate HfaAlbuterol Sulfate14$319
Tramadol Hcl37$299
Metoprolol Succinate17$245
Atorvastatin Calcium47$220
Duloxetine Hcl11$212
Doxycycline Monohydrate23$189
Carvedilol36$183
Cefdinir17$160
Azithromycin33$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$15,93425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →